Department of Biomolecular Sciences, Section of Clinical Biochemistry, Unit of Cell Biology, University Carlo Bo of Urbino, I-61029 Urbino (PU), Italy.
BMC Med. 2011 Aug 11;9:95. doi: 10.1186/1741-7015-9-95.
Molecular and biochemical expressions of matrix metalloproteinases in breast cancer tissue and cells offers promise in helping us understand the breast cancer microenvironment, and also in the future it is hoped this will improve its detection, treatment and prognosis. In a retrospective study recently published in BMC Cancer, microenvironment predisposing to breast cancer progression, metastatic behavior and the expression of matrix metalloproteinase-1 (MMP-1) and its correlation with well-known biochemical, molecular and clinicopathologic factors in breast cancer cells and cancer-associated stromal cells was examined; this study also analyzed patient survival in different breast cancer subtypes. The positive correlation in breast tumor and stromal cells between MMP-1 expression and several markers of tumor grade and stage provide us with some useful new insights into important questions about the molecular profiling of the stromal microenvironment in metastatic breast cancer. The study showed that MMP-1 expression is strongly associated with poor clinical outcome, so now we look forward to future larger studies in breast cancer patients in which we can relate wider MMP molecular profiling to identify lethal tumor and stromal microenvironments predisposing to breast cancer progression, metastatic behavior and poor prognosis. Please see related article http://www.biomedcentral.com/1471-2407/11/348.
乳腺癌组织和细胞中基质金属蛋白酶的分子和生化表达有望帮助我们了解乳腺癌的微环境,并且未来有望提高其检测、治疗和预后效果。在最近发表在 BMC Cancer 的一项回顾性研究中,研究了有利于乳腺癌进展、转移行为以及基质金属蛋白酶-1(MMP-1)表达的微环境,及其与乳腺癌细胞和癌相关基质细胞中已知的生化、分子和临床病理因素的相关性;本研究还分析了不同乳腺癌亚型患者的生存情况。在乳腺癌肿瘤和基质细胞中,MMP-1 表达与肿瘤分级和分期的几个标志物之间呈正相关,这为我们提供了一些有关转移性乳腺癌基质微环境分子分析的重要问题的新见解。研究表明,MMP-1 表达与不良临床结局密切相关,因此我们期待未来在乳腺癌患者中进行更大规模的研究,我们可以通过更广泛的 MMP 分子分析来确定导致乳腺癌进展、转移行为和不良预后的致命肿瘤和基质微环境。请参阅相关文章 http://www.biomedcentral.com/1471-2407/11/348。